Lactobacillus gasseri OLL2716 as a probiotic in clarithromycin-resistant Helicobacter pylori infection

J Gastroenterol Hepatol. 2003 Aug;18(8):986-91. doi: 10.1046/j.1440-1746.2003.03102.x.

Abstract

Backgrounds and aim: Clarithromycin (CAM)-resistant Helicobacter pylori sometimes offers serious problems with eradication by antibiotics. The aim of this study was to determine whether a probiotic can be an alternative therapy in CAM-resistant Hp infection.

Methods: The effects of Lactobacillus gasseri (strain OLL2716) on the growth of CAM-susceptible and CAM-resistant H. pylori and interleukin (IL)-8 production provoked by these strains were examined by in vitro experiments. Moreover, mice were infected with these CAM-susceptible or CAM-resistant H. pylori, and were treated with CAM or L. gasseri.

Results: In vitro experiments demonstrated that L. gasseri inhibited the growth of H. pylori and suppressed H. pylori-associated IL-8 production. Such effects were noted in CAM-resistant and CAM-susceptible H. pylori. Similarly, in an in vivo model of H. pylori infection, H. pylori colonization was significantly decreased by L. gasseri.

Conclusion: Therefore, L. gasseri was found to act as a probiotic in CAM-resistant H. pylori infection.

MeSH terms

  • Animals
  • Anti-Bacterial Agents / pharmacology*
  • Clarithromycin / pharmacology
  • Drug Resistance, Bacterial
  • Helicobacter Infections / drug therapy*
  • Helicobacter pylori / drug effects*
  • Interleukin-8 / metabolism
  • Lactobacillus*
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Microbial Sensitivity Tests
  • Probiotics / pharmacology*

Substances

  • Anti-Bacterial Agents
  • Interleukin-8
  • Clarithromycin